U Petrausch1, P Samaras1, S R Haile2, P Veit-Haibach3, J D Soyka3, A Knuth1, T F Hany3, A Mischo1, C Renner1, N G Schäefer4. 1. Department of Oncology, University Hospital Zurich. 2. Biostatistics Unit, Institute of Social and Preventive Medicine, University of Zurich. 3. Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Zürich, Switzerland. 4. Department of Oncology, University Hospital Zurich; Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Zürich, Switzerland. Electronic address: niklaus.schaefer@usz.ch.
Abstract
BACKGROUND: The purpose of this study was to evaluate the impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) during follow-up of patients with diffuse large B-cell lymphoma (DLBCL) being in complete remission or unconfirmed complete remission after first-line therapy. PATIENTS AND METHODS: DLBCL patients receiving FDG-PET/CT during follow-up were analyzed retrospectively. Confirmatory biopsy was mandatory in cases of suspected disease recurrence. RESULTS: Seventy-five patients were analyzed and 23 (30%) had disease recurrence. The positive predictive value (PPV) of FDG-PET/CT was 0.85. Patients >60 years [P = 0.036, hazard ratio (HR) = 3.82, 95% confidence interval (CI) 1.02-7.77] and patients with symptoms indicative of a relapse (P = 0.015; HR = 4.1; 95% CI 1.20-14.03) had a significantly higher risk for relapse. A risk score on the basis of signs of relapse, age >60 years, or a combination of these factors identified patients at high risk for recurrence (P = 0.041). CONCLUSIONS: FDG-PET/CT detects recurrent DLBCL after first-line therapy with high PPV. However, it should not be used routinely and if only in selected high-risk patients to reduce radiation burden and costs. On the basis of our retrospective data, FDG-PET/CT during follow-up is indicated for patients <60 years with clinical signs of relapse and in patients >60 years with and without clinical signs of relapse.
BACKGROUND: The purpose of this study was to evaluate the impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) during follow-up of patients with diffuse large B-cell lymphoma (DLBCL) being in complete remission or unconfirmed complete remission after first-line therapy. PATIENTS AND METHODS: DLBCL patients receiving FDG-PET/CT during follow-up were analyzed retrospectively. Confirmatory biopsy was mandatory in cases of suspected disease recurrence. RESULTS: Seventy-five patients were analyzed and 23 (30%) had disease recurrence. The positive predictive value (PPV) of FDG-PET/CT was 0.85. Patients >60 years [P = 0.036, hazard ratio (HR) = 3.82, 95% confidence interval (CI) 1.02-7.77] and patients with symptoms indicative of a relapse (P = 0.015; HR = 4.1; 95% CI 1.20-14.03) had a significantly higher risk for relapse. A risk score on the basis of signs of relapse, age >60 years, or a combination of these factors identified patients at high risk for recurrence (P = 0.041). CONCLUSIONS: FDG-PET/CT detects recurrent DLBCL after first-line therapy with high PPV. However, it should not be used routinely and if only in selected high-risk patients to reduce radiation burden and costs. On the basis of our retrospective data, FDG-PET/CT during follow-up is indicated for patients <60 years with clinical signs of relapse and in patients >60 years with and without clinical signs of relapse.
Authors: Carrie A Thompson; Herve Ghesquieres; Matthew J Maurer; James R Cerhan; Pierre Biron; Stephen M Ansell; Catherine Chassagne-Clément; David J Inwards; Thérèse Gargi; Patrick B Johnston; Emmanuelle Nicolas-Virelizier; William R Macon; Marie Peix; Ivana N Micallef; Catherine Sebban; Grzegorz S Nowakowski; Luis F Porrata; George J Weiner; Thomas E Witzig; Thomas M Habermann; Brian K Link Journal: J Clin Oncol Date: 2014-09-29 Impact factor: 44.544
Authors: C Y Cheah; M S Hofman; M Dickinson; A Wirth; D Westerman; S J Harrison; K Burbury; M Wolf; H Januszewicz; K Herbert; H M Prince; D A Carney; D S Ritchie; R J Hicks; J F Seymour Journal: Br J Cancer Date: 2013-06-27 Impact factor: 7.640
Authors: Yu Ri Kim; Soo-Jeong Kim; June-Won Cheong; Yundeok Kim; Ji Eun Jang; Hyunsoo Cho; Haerim Chung; Yoo Hong Min; Woo Ick Yang; Arthur Cho; Jin Seok Kim Journal: Korean J Intern Med Date: 2020-06-19 Impact factor: 2.884